BioSpace News Archive

Drug Development

Merck and Gilead Pause HIV Study out of “Abundance of Caution”

Both Gilead Sciences and Merck announced they were pausing a Phase II trial of islatravir and lenacapavir in HIV.

November 24, 2021
·
3 min read
·
Mark Terry
Genetown

Merck and Dragonfly, Together Again

Merck opted to license its second TriNKET immunotherapy candidate from Dragonfly Therapeutics. The option came one year after Merck licensed its first immunotherapy candidate.

November 24, 2021
·
2 min read
·
Alex Keown
Spatial Genomics & Transcriptomics Market: Growing incidence of various genetic disorders to drive the market

The spatial genomics & transcriptomics market is prognosticated to bring profitable growth during the assessment period of 2019-2027.

November 24, 2021
·
8 min read
Rapid Test Market: The need for diagnostic tests across various domains within healthcare has created commendable growth opportunities

The demand within the global rapid test market has been rising on account of the popularity of preliminary screening across medical facilities.

November 24, 2021
·
5 min read
Radiopharmaceutical Market with New Business Opportunities Discussed | Top Players - Siemens Healthineers, GE Healthcare

According to the report, the global radiopharmaceuticals market was valued at US$ 3.9 Bn in 2020 and is projected to expand at a CAGR of 7.3% from 2021 to 2031.

November 24, 2021
·
5 min read
Prefilled Formalin Vials Market Report is witnessing Constant Growth to 2028 | TMR Research Study

Prefilled formalin vials are clarified containers that allow easy visualization of samples in the healthcare industries.

November 24, 2021
·
5 min read
Drug Development

Kintor Pharma Receives IND Clearance by NMPA for KX-826’s Pivotal Study to Treat Male Alopecia Patients

Kintor Pharmaceutical Limited today announced that the IND application for the pivotal study (phase III stage) of pyrilutamide (KX-826), a potential first-in-class drug developed by Kintor Pharma.

November 24, 2021
·
2 min read
Business

Zerion Pharma ApS extends its licensing agreement with Rousselot B.V to exploit Dispersome® technology platform

Rousselot B.V. and Zerion Pharma ApS announce today that they have strengthened their partnership through an extension of an exclusive license agreement entered into in 2019.

November 24, 2021
·
4 min read
Business

Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced financial results for the third quarter ended September 30, 2021.

November 24, 2021
·
15 min read
BioMidwest

Cardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection System

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) has initiated a voluntary recall of unused WIRION Embolic Protection Systems (WIRION) due to complaints of filter breakage during retrieval.

November 24, 2021
·
2 min read